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Abstract
Background: Aberrant DNA methylation at imprinted loci is an important molecular mechanism contributing to
several developmental and pathological disorders including cancer. However, knowledge about imprinting defects due
to DNA methylation changes is relatively limited in hepatocellular carcinoma (HCC), the third leading cause of cancer
death worldwide. Therefore, comprehensive quantitative DNA methylation analysis at imprinted loci showing ~50 %
methylation in healthy liver tissues was performed in primary HCC specimens and the peritumoural liver tissues.
Results: We found frequent and extensive DNA methylation aberrations at many imprinted loci in HCC. Unsupervised
cluster analysis of DNA methylation patterns at imprinted loci revealed subgroups of HCCs with moderate and severe
loss of methylation. Hypomethylation at imprinted loci correlated significantly with poor overall survival (log-rank test,
p = 0.02). Demethylation at imprinted loci was accompanied by loss of methylation at LINE-1, a commonly used marker
for global DNA methylation levels (p < 0.001). In addition, we found that loss of methylation at imprinted loci correlated
with the presence of a CTNNB1 mutation (Fisher’s exact test p = 0.03). Re-analysis of publically available genome-wide
methylation data sets confirmed our findings. The analysis of benign liver tumours (hepatocellular adenoma (HCA) and
focal nodular hyperplasia (FNH)), the corresponding adjacent liver tissues, and healthy liver tissues showed that aberrant
DNA methylation at imprinted loci is specific for HCC.
Conclusions: Our analyses demonstrate frequent and widespread DNA methylation aberrations at imprinted loci in
human HCC and identified a hypomethylated subgroup of patients with shorter overall survival.
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Background
Genomic imprinting represents a deviation from
Mendelian laws in which gene expression is regulated
to originate only from one allele, either the paternal
or the maternal one [1]. Establishment of imprinting
takes place during gametogenesis and plays an im-
portant role in the regulation of embryogenesis and
foetal development [2]. The allele-specific expression
is regulated by epigenetic mechanisms especially DNA
methylation. In the genomic context, imprinted genes
are commonly located in clusters [3]. Each imprinted
gene or cluster is surrounded by differentially methylated
regions (DMR) wherein methylation appears also in a
parent-specific pattern [4]. Regulation of imprinted genes
or clusters is controlled by these DMRs in which the pat-
terns are transmitted from male and female gametes to
the zygote, reprogrammed during peri-implantation and
tissue differentiation, and then firmly maintained
throughout somatic development and in adult tissues
[3]. Aberrant regulation during imprinting establish-
ment has been associated with several pathological
disorders including cancer. Moreover, embryogenesis
and carcinogenesis often share common features espe-
cially in the involved genes, signalling pathways, as
well as the regulatory mechanisms [5].* Correspondence: Lehmann.Ulrich@MH-Hannover.de1Institute of Pathology, Medizinische Hochschule Hannover, Carl-Neuberg-Str.
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Many imprinted genes are suggested to play a crucial
role in driving the oncogenic switch or suppressing the
tumour development. Therefore, deregulation of their ex-
pression has also been implicated in various human
cancers [6, 7]. Imprinting defects at 11p15.5 locus in
Beckwith-Wiedemann syndrome (BWS) confer the pa-
tients with high risk of cancer compared to the general
population [8]. The first description of DNA methylation-
mediated loss of imprinting in cancer is also described in
this H19-IGF2 locus in Wilms’ tumour [9]. Although the
mechanisms for imprint defects at the H19-IGF2 locus
vary among different tumour types, gain of methylation at
the maternal allele is the most common feature. Hyperme-
thylation at H19-DMR causes biallelic expression of IGF2
accompanied by silencing of H19 [10]. Loss of imprinting
in P73 can be caused by genetic deletion as reported for
neuroblastoma [11] or by aberrant DNA methylation as
reported for leukaemia and lymphoma [12]. Genetic dele-
tion of ARHI is reported in breast and ovarian cancer [13].
Since then, several other imprinted genes are implicated
in carcinogenesis of various malignancies.
In hepatocellular carcinoma (HCC), the fifth most fre-
quent cancer worldwide and the third leading cause of
cancer related death, relatively little is known about the
dysregulation of DNA methylation at imprinted loci.
Most of the studies in HCC related to imprinting defects
focused only on a single locus, namely IGF2/H19. Our
initial efforts to study epigenetic instability of imprinted
genes in HCC have revealed frequent DNA methylation
aberrations resulting in biallelic expression and allele
switching at the DLK1-MEG3 imprinting cluster [14]
and identified the well-known tumour suppressor gene
RB1 as a new target for imprint dysregulation in human
HCC [15].
Currently, 97 human genes are confirmed to be
imprinted [16] leaving the possibility that more imprinted
genes contribute to the development of liver malignancy a
likely scenario. Analysis of various imprinted loci to deter-
mine basal DNA methylation levels in several healthy tis-
sues including the liver has been performed [17]. We
therefore extended our analysis to imprinted loci demon-
strating approximately 50 % (35–65 %) methylation in
healthy liver samples as shown by Woodfine et al. [17].
Using our HCC cohort, frequent and extensive DNA
methylation aberrations at imprinted loci could be ob-
served and used for HCC classification. A subgroup of
HCC showing widespread loss of methylation at imprinted
loci correlates significantly with poor survival identifying
imprint instability as a potentially new prognostic marker
in HCC.
During the course of this study, Lambert et al. [18]
published a survey of DNA methylation changes at
imprinted loci in HCC. This study, which is based on
the re-analysis of previous data from the same group
[19], nicely complements our data and is discussed in
detail below.
Results
Aberrant DNA methylation in imprinted loci in HCC
specimens
A total of 34 differentially methylated regions (DMRs) de-
scribed to regulate genomic imprinting in humans and
displaying allele-specific DNA methylation in healthy hu-
man liver [17] were analysed in primary HCC specimens
(n = 40), the corresponding adjacent liver tissues (n = 34),
and healthy liver samples (n = 5) using high-resolution
quantitative pyrosequencing. The very low variability in
the five unrelated control specimens represents the
“healthy ground state” of DNA methylation at the loci
under study in normal hepatocytes and demonstrates the
tight control of the maintenance of DNA methylation pat-
terns at imprinted loci under physiological conditions.
Compared to the peritumoural liver tissues and healthy
liver specimens, differential DNA methylation in HCC
was shown in altogether 25 out of 34 DMRs (Fig. 1 and
Table 1). At 14 loci, a substantial gain of methylation was
found, whereas a strong loss of methylation was detected
at 23 loci, with 11 loci showing gains as well as losses of
DNA methylation in different patient samples. This com-
plex pattern is only discernible if the results for each sam-
ple are analysed and displayed individually as in Fig. 1. A
few loci display already in the adjacent liver specimens
clearly discernible alterations in DNA methylation
(DIRAS3(2), NAP1L5,MAGEL2, and GRBRB3) supporting
the concept that loss of proper regulation at imprinted
loci is an early event in the development of human cancer
[20]. Since the ground state of DNA methylation at
imprinted loci is 50 %, tumour tissue specimens may dis-
play gains or losses of methylation. This might lead to the
situation that the mean DNA methylation level in tumour
specimens is not statistically significantly different from
the mean value in healthy tissue despite the presence of
substantial deregulation of DNA methylation. This sce-
nario is exemplified by the RB1 locus (see Fig. 1, second
part, fourth row). Therefore, we tested (employing the F-
test) also whether the variances in DNA methylation levels
differ between the three groups (tumour, adjacent, healthy
liver). For the majority of loci, the variance of DNA
methylation levels in tumour specimens is significantly
different (p < 0.0001, see Additional file 1: Table S1 for de-
tails) from the variance in the adjacent non-tumourous
tissue indicating widespread and pronounced epigenetic
instability at imprinted loci in human HCC.
From Table 1, it is discernible that most alterations in
DNA methylation affect whole chromosomal regions in-
volving several imprinted genes and DMRs simultan-
eously, e.g., on chromosome 11p15, 14q32, or 15q11.
However, at closer inspection, a complex picture
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becomes apparent. At chromosome 11p15, for example,
the H19 DMR displays gains and losses, the IGF2 DMRs
only losses, whereas KCNQ1DN displays only gains of
DNA methylation.
DNA methylation at imprinted loci and global DNA
methylation
Unsupervised cluster analysis of quantitative DNA methy-
lation levels in our HCC cohort revealed three distinct
subgroups: one displaying marked hypomethylation, a sec-
ond displaying only subtle hypomethylation, and a third
characterized by hypermethylation (Fig. 2). In the next
step, global DNA methylation was analysed in every pa-
tient sample employing the measurement of LINE-1
methylation levels as surrogate marker for global DNA
methylation levels [21, 22]. The group with only subtle
losses of DNA methylation at imprinted loci already dem-
onstrated a significant decrease in LINE-1 methylation
compared to the hypermethylated group (Fig. 3). The
HCC group characterized by gains of DNA methylation at
imprinted loci showed no change in global DNA methyla-
tion level if compared with adjacent liver tissue specimens
and healthy liver samples (Additional file 2: Figure S1).
These observations argue against a simple direct con-
nection between global DNA methylation and methyla-
tion patterns at imprinted loci and support a model in
which these mechanisms are regulated independently
from each other.
Re-analysis of genome-wide DNA methylation analysis at
imprinted loci in primary HCC specimens
In order to validate the above described findings, we re-
analysed publicly available data of genome-wide DNA
methylation analyses in HCC. Two methylom data sets,
i.e., Neumann et al. [23] and Shen et al. [24], were re-
trieved and re-analysed for DNA methylation changes at
imprinted loci. Methylation profiles of imprinted genes
from both cohorts demonstrated patterns very similar to
our findings (Additional file 3: Figure S2). Performing
cluster analysis of methylation profiles of imprinted loci
contained within these genome-wide DNA methylation
data sets, also three subgroups could be identified: heavy
and subtle loss of methylation as well as hypermethyla-
tion. As a surrogate marker for global DNA methylation
levels, the mean β values from all CpG sites contained
Fig. 1 Aberrant DNA methylation at multiple imprinted loci in primary
HCC. All individual methylation values quantified with high-resolution
pyrosequencing from 40 primary HCC specimens, 34 adjacent
liver specimens, and 5 healthy liver tissues are displayed with
scatter plots. Black triangles represent HCCs and grey triangles the
adjacent liver tissues. The results of the Mann Whitney U test are
indicated: **p < 0.01; ***p < 0.001. Additional file 1: Table S1 contains a
complete compilation of the results of all statistical calculations
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within the Illumina 27K methylation array (excluding
the sex chromosomes) were calculated and compared
among the three subgroups. Significantly reduced global
DNA methylation levels (measured as mean β values)
were already observed in the group displaying only sub-
tle hypomethylation at imprinted loci (Additional file 4:
Figure S3). There was no significant difference between
the global DNA methylation level in the group charac-
terized by gain of DNA methylation at imprinted loci on
the one hand and healthy liver samples and adjacent
liver tissues on the other hand, nicely confirming the
complex relationship between global DNA methylation
Table 1 Gains and losses of DNA methylation at imprinted loci in HCC
Tumor Adjacent
Loss Gain Loss + gain Loss Gain Loss + gain
DIRAS3(3) 1p31 +
DIRAS3(2) 1p31 ++ ++ • ++ ++ •
ZBDF2 2q33 ++ +
NAP1L5 4q22 ++ ++ • ++ ++ •
ZAC 6q24 (+) (+)








KvDMR 11p15 (+) (+)




MEG3DMR(1) 14q32 ++ + •
MEG3DMR(2) 14q32 ++ + •
MEG3DMR(3) 14q32 ++ + •
MKRN3 15q11 ++
MAGEL2 15q11 ++ +
NDN 15q11 (+)
SNRPN 15q11 ++ + •
GABRB3 15q11 ++ +
NLRP2 19q13 ++ (+) (•)
PEG3 19q13 +
USP29 19q13 + +
ZIM3 19q13 + +
NNAT 20q11
L3MBTL 20q13 (+)
GNAS-XL 20q13 ++ ++ •
NESP 20q13 ++ ++ •
Sum 23 (+3) 14 (+2) 11 4 (+2) 2 2
The DNA methylation levels for all loci presented in Fig. 1 are classified after visual inspection of the data. The loci are arranged according to their
chromosomal localisation
(+) slight alterations, + alterations, ++ strong alterations,• gain + loss at the same locus
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Fig. 2 Cluster analysis of methylation levels at imprinted loci. DNA methylation patterns at imprinted loci separate HCC into three subgroups.
Unsupervised clustering of methylation levels at imprinted loci was performed. Upper panel: red = gain of methylation, blue =moderate loss of
methylation, and green = severe loss of methylation. Lower panel: distribution of CTNNB1 (β-catenin) mutations
Fig. 3 Aberrations of DNA methylation at imprinted loci and global DNA methylation levels. Loss of methylation at imprinted loci is accompanied
by reduced DNA methylation at LINE-1 sequences which serves as a surrogate marker for global DNA methylation level [21]. DNA methylation at
LINE-1 sequences is significantly lower in the subgroup with subtle loss of methylation. The difference is even more pronounced in the subgroup
displaying severe loss of methylation at imprinted loci. ***p < 0.001
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and methylation patterns at imprinted loci observed in
our cohort.
CTNNB1 mutations and the correlation with methylation
at imprinted loci
Mutations of the CTNNB1 gene have been previously
described in a subgroup of HCCs with extensive gain of
DNA methylation at tumour suppressor loci [25]. In our
cohort, we found that 33 % (11/40) of HCCs harboured
activating beta-catenin mutations. However, different
from the previous study by Nishida et al. [25], in our co-
hort, CTNNB1 mutations were enriched in HCC sam-
ples showing loss of DNA methylation at imprinted loci
(Fig. 2, Fisher’s exact test p = 0.03).
DNA methylation patterns of imprinted loci in benign
liver tumours
To clarify whether aberrant DNA methylation at
imprinted loci is cancer cell specific, methylation analysis
was performed in benign hepatocellular adenoma (HCA)
that show minimal tendency for malignant transformation
[26] as well as in focal nodular hyperplasia (FNH), charac-
terized by a strong but benign increase in cell proliferation
[27]. None of the benign liver tumour samples and also
none of the corresponding adjacent liver tissues showed
aberrant DNA methylation at any of the imprinted loci
under study (Additional file 5: Figure S4). This demon-
strates that DNA methylation aberrations at imprinted
loci are specific events in the process of malignant trans-
formation of hepatocytes and not due to a mere increase
in cell proliferation which might reduce the fidelity of the
maintenance of DNA methylation patterns.
Methylation of imprinted loci and overall survival
Given the ability of methylation profiles at imprinted loci
to divide HCCs reproducibly in independent data sets into
three distinct classes, we then ascertained the clinical rele-
vance of this finding. Comparing HCC cases showing loss
of methylation with the hypermethylated subgroup
revealed that those with loss of methylation showed a
significantly shortened survival (Fig. 4, log-rank test, p =
0.02). Patient age was not significantly different between
hypo- and hypermethylated subgroups arguing against dif-
ferent age-distribution as a confounding factor.
Discussion
Epigenetic instability has been demonstrated as a hall-
mark of cancer. During the development and progres-
sion of cancers, epigenetic aberrations are shown to
occur in much higher frequency than genetic alterations
[28]. DNA methylation and genomic imprinting are re-
programmed during foetal development, and misregula-
tion of these processes has been associated with several
pathological processes including cancer [29]. In HCC, as
one of the major types of human cancer, only relatively
few studies have addressed DNA methylation aberra-
tions at imprinted loci so far (see [14] and references
therein). Studies of imprinting in HCC are mostly deal-
ing with a single locus, i.e., IGF2-H19. Here, by analysing
multiple imprinted loci, we showed extensive DNA
methylation aberrations in primary HCC specimens.
Using DNA methylation patterns at imprinted loci, we
demonstrated sub-classification of HCC in which loss of
methylation correlates with poor prognosis. This pro-
vides the first evidence that DNA methylation changes
at imprinted loci can be potentially useful to predict
Fig. 4 Survival analysis. The overall survival of HCC patients displaying hypomethylation at imprinted loci is significantly lower than in patients with
retention of imprint methylation. The Kaplan-Meier plot shows survival of two groups (loss and gain of methylation at imprinted loci), log-rank test
p = 0.02, median survival 41 and 156 weeks, respectively
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clinical outcomes in HCC and complements recently de-
scribed molecular classification systems [30]. These find-
ings also provide crucial evidence that in addition to
genomic profiling [31], epigenomic profiling is necessary
for a comprehensive understanding of the molecular al-
terations underlying the development of human HCC.
At four loci (DIRAS3(2), NAP1L5, MAGEL2, and
GRBRB3), distinct changes in DNA methylation are
already detectable in the peritumoural adjacent liver tis-
sue. Already more than 60 years ago, it has been
proposed that genetic changes take place in precancer-
ous cells generating a pool of cells from which the ma-
lignantly transformed cancer cells arise, a phenomenon
termed “field cancerization” [32]. For several malig-
nancies, also epigenetic field defects preceding the
development of full blown malignancy have been
described [33, 34]. So far, these studies did not examine
systematically the involvement of imprinted loci in the
liver [35]. Therefore, future studies have to address the
expression of the above mentioned loci in precancerous
liver conditions like cirrhosis or chronic hepatitis.
From Table 1, it is obvious that the majority of
changes in DNA methylation at imprinted loci are repre-
sented by loss of methylation. However, this does not al-
ways lead to an increase of mRNA expression as one
might expect from the usually repressive effect of DNA
methylation. Loss of DNA methylation at imprinted loci
can lead to reduction in mRNA expression due to in-
creased expression of anti-sense RNAs or interfering
RNAs, as shown for the RB1 locus [15, 36].
Generalized loss of methylation that predominantly af-
fects repetitive DNA elements has been associated with
genetic instability [22]. Demethylation at the repetitive
elements can initiate retrotransposition of the transpos-
able elements causing deregulation of the neighbouring
genes, attenuation of cell cycle checkpoint control, and
abrogation of DNA repair systems [37, 38]. Therefore,
aggressive tumour behaviour and poor survival are more
evident in the subgroup of gastric cancer with hypome-
thylation at repetitive elements [39].
Recently, Lambert et al. [18] reported also on DNA
methylation aberrations at imprinted loci in human
HCC. The results are based on the re-analysis of previ-
ously published methylation data from the same group
[19] obtained by the GoldenGate™ methylation array
from Illumina. Despite a different perspective (Lambert
et al.: risk factor exposure, this study: survival), a differ-
ent conceptual approach (Lambert et al.: hypothesis-free
analysis of all loci represented on the Illumina Golden-
Gate™ array, this study: hypothesis-driven analysis of
only DMRs displaying 50 % methylation in human
healthy liver tissue) and a different methodological basis
(Illumina GoldenGate versus pyrosequencing) both stud-
ies complement nicely each other. Together, they
unequivocally confirm that aberrant DNA methylation
at imprinted loci is a frequent event in human HCC,
which might be exploited in the future as a new bio-
marker. The differences between both studies are mainly
due to the fact that many genes are represented by only
one or two CpG sites on the GoldenGate array, that not
all regions analysed by us are represented on the Illumina
array, and that our approach focused from the beginning
not only on genes but also on imprint control regions.
Although moderate aberrant DNA methylation has been
reported in some tumour suppressor genes in hepatocellu-
lar adenoma [40, 41], we do not observe any methylation
aberration at imprinted loci in this benign liver tumour
and also not in the benign proliferation focal nodular
hyperplasia [27]. These results indicate that aberrant
methylation at imprinted loci is a specific event in the
malignant transformation of hepatocytes and not only a
by-product of increased proliferation accompanied by
reduced fidelity of DNA methylation maintenance.
Deregulation of DNA methylation at imprinted loci is
obviously independent from generalized hypomethylation
in repetitive sequences in HCC. As clearly discernible
from Fig. 3, subtle loss of methylation at imprinted loci is
accompanied by a substantial decrease of LINE1 methyla-
tion levels whereas gain of methylation at these loci occurs
in the context of unaltered LINE1 methylation. Several
genes required for protection and maintenance of imprint-
ing have been identified, particularly ZFP57 and TRIM28/
KAP1. The protein products of these genes form a chro-
matin modifier complex and act specifically at the imprint
control regions [42, 43]. Within this complex, ZFP57 rec-
ognizes the imprinting control regions and TRIM28 re-
cruits DNMT1 to stabilize the imprinting marks [42, 44].
Ablation of ZFP57 and disruption of TRIM28 lead to spe-
cific loss of methylation at the imprinting control regions
in mice [45]. However, how loss of ZFP57 or TRIM28
function is related to extensive hypomethylation in
imprinted loci in cancer cells is currently unknown. Up-
regulation of TET family proteins that are involved in an
active DNA demethylation process through the generation
of 5-hydroxymethyl-cytosine has also been implicated in
the development of human cancer [46]. TET2 is also cru-
cial for proper imprint regulation and might be involved
in the observed widespread demethylation at imprinted
loci in HCC [47]. Heterochromatin with H3K9me3 marks
is able to recruit STELLA/PGC7 to maternal alleles and
to some paternal DMRs protecting them from active de-
methylation by TET family proteins. Loss of PGC7 func-
tion is also likely to be an initiation event for generalized
loss of DNA methylation at imprinted loci [48, 49].
Dysregulation of Wnt/β-catenin signalling has been
implicated in liver carcinogenesis in which β-catenin
mutations are observed in 20–30 % of HCCs [50–52].
CTNNB1 mutations confer activation of the Wnt
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pathway leading to disturbance of cell-cell contacts and
stimulation of cell proliferation and migration. The con-
nection between CTNNB1 mutations and frequent
hypermethylation of tumour suppressor genes has been
first described by Nishida et al. [25]. However, the mo-
lecular mechanism of this correlation remains unclear.
In that study, 18 well-described tumour suppressor loci
and three intergenic loci with unknown function were
analysed using low-resolution semiquantitative COBRA
methodology [53]. Imprinted loci were not studied by
Nishida et al. In our HCC cohort, β-catenin is mutated
more frequently in HCC specimens with loss of methyla-
tion at imprinted loci. This highlights important differ-
ences in the regulation of DNA methylation patterns at
tumour suppressor genes and imprinted loci. Thus, the
mechanism linking CTNNB1 mutations and DNA methy-
lation aberrations still needs further investigations.
Conclusions
This study shows frequent and extensive DNA methyla-
tion aberrations at imprinted loci in human HCC but
not in the adjacent liver tissues. In our HCC cohort, hy-
pomethylation at imprinted loci correlates with global loss
of DNA methylation (measured as LINE1 methylation),
frequent CTNNB1 exon3 mutation, and shortened overall
survival. Therefore, DNA methylation at imprinted con-
trol regions represents a promising new biomarker for
detection, sub-classification, as well as prognosis in HCC.
Methods
Patient samples and cell lines
A collection of primary human liver specimens were ob-
tained from 40 HCC, 10 HCA, and 5 FNH patients who
underwent surgery at the Medizinische Hochschule
Hannover, snap frozen in liquid nitrogen and subse-
quently stored at −80 °C. All patient samples were
analysed anonymously following a protocol approved by
the local ethics committee (“Ethik-Kommission der
Medizinischen Hochschule Hannover”, head: Prof. Dr.
Tröger). Verification of tumour cell content to be at
least 70 % was accomplished by an experienced patholo-
gist using serial reference sections from each snap frozen
specimen. Basic clinicopathological variables of the pa-
tients are summarized in Additional file 6: Table S2.
Seven HCC cell lines (HLE, HLF, HuH7, HepG2, Hep3B,
SNU182, and SNU387) and two immortalized hepato-
cyte lines (THLE-2 and THLE-3) were obtained from
American Tissue Culture Collection (ATCC, Rockville,
MD, USA) and cultivated under conditions recom-
mended by ATCC. The proper identity of all cell lines
was validated using short tandem repeat (STR) profiling
following the protocol provided by the German Collec-
tion of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany). All experiments using cell
lines were performed at sub-confluent cellular density
allowing exponential growth.
DNA and RNA extraction
Extraction of high molecular weight DNA from the snap
frozen primary specimens was performed by digestion
with proteinase K (Merck, Darmstadt, Germany) followed
by phenol/chloroform purification (ROTI® Carl Roth
GmbH, Karlsruhe, Germany) according to standard proto-
cols. Total RNA was extracted using TRIZOL™ reagent
(Invitrogen, Darmstadt, Germany) following the instruc-
tion by the manufacturer.
Bisulfite conversion and methylation analysis
For DNA methylation analysis, a total of 1 μg genomic
DNA was treated with sodium bisulfite using the EZ
DNA Methylation Kit™ (Zymo Research, HiSS Diagnos-
tics, Freiburg, Germany) according to the manufacturer’s
protocol. For each PCR amplification, approximately
25 ng of the bisulfite modified DNA were used. DNA
methylation analysis was performed employing pyrose-
quencing as described previously [54]. All primer se-
quences are listed in Additional file 7: Table S3. The
DNA methylation level for a given gene in a sample was
calculated as the mean of the individual methylation
levels of all CpG dinucleotides under study obtained
from two independent pyrosequencing runs. The soft-
ware Pyro-Q-CpG™ (Qiagen, Hilden, Germany) was used
for calculating DNA methylation levels of each individ-
ual CpG dinucleotide. “Hypermethylated” and “hypo-
methylated” are defined as methylation value above and
below mean of the adjacent liver tissue plus two times
the standard deviation, respectively (normal range =
meanadj ± 2 × StD) [40].
CTNNB1 mutation analysis
The presence of mutations in exon 3 of the CTNNB1 gene
was analysed in primary HCC specimens using primers as
described before [55]. For the sequencing reaction, the
GenomeLab™ DTCS Quick Start kit (Beckman Coulter,
Krefeld, Germany) and GenomeLab™ Genetic Analysis
System (Beckman Coulter, Brea, CA) were used following
the manufacturer’s instructions without deviation.
Statistical analysis
Cluster analysis of DNA methylation values at imprinted
loci was performed using Qlucore Omics Explorer v2.2
(Qlucore, Lund, Sweden). For further statistical analyses,
GraphPad Prism (version 5.01 for Windows, La Jolla, CA,
USA) was used. The Mann Whitney U test was utilized to
compare continuous variables and χ2 test for relationships
between categorical variables. More than two groups were
compared by one-way ANOVA adjusted to non-
parametric conditions (Kruskal-Wallis test). Differences in
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variances between two groups were assessed by using the
F-test. To compare survival of HCC patients, Kaplan-
Meier curves were constructed and log-rank (Mantel-
Cox) test was used. For those comparisons, p < 0.05 was
considered as statistically significant.
Additional files
Additional file 1: Table S1. Compilation of all p values for all statistical
calculations performed for the data displayed in Fig. 1.
Additional file 2: Figure S1. Global DNA methylation levels (measured
by LINE1 methylation).
Additional file 3: Figure S2. Cluster analysis of methylation patterns at
imprinted loci in HCC using Illumina 27K methylation array from (A)
Heidelberg n = 63) [23] and (B) Taiwanese cohort (n = 62) [24] shows
subgrouping of HCC into three groups: hypermethylation and moderate
and severe hypomethylation.
Additional file 4: Figure S3. Global DNA methylation level in
correlation to DNA methylation at imprinted loci.
Additional file 5: Figure S4. DNA methylation analysis at imprinted
loci in HCA, FNH, the adjacent liver tissues, and healthy liver samples.
Additional file 6: Table S2. Clinopathological variables of all HCC, HCA,
and FNH patients involved in this study.
Additional file 7: Table S3. List of primers used in this study.
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